Şunu aradınız:: hairy cell leukaemia (İngilizce - Maltaca)

hairy cell leukaemia
lewkimja tal-hairy cell

treatment of patients with hairy cell leukaemia.
il-kura ta’ pazjenti bil-lewkimja tal-hairy cell.

litak is indicated for the treatment of hairy cell leukaemia.
litak huwa indikat għat-trattament ta’ lewkimja tac-ċelluli ċiljati (‘hairy cell leukaemia’).

secondary malignancies are expected to occur in patients with hairy cell leukaemia.
malinni sekondarji huma mistennija li jseħħu f’pazjenti li għandhom lewkimja taċ-ċelluli ċiljati (‘hairy cell leukaemia’).

litak has been examined in one main study involving 63 patients with hairy cell leukaemia.
litak ġie eżaminat fi studju wieħed ewlieni bis- sehem ta ’ 63 pazjent bil- lewċemija taċ- ċelloli tax - xagħar.

high doses of co-trimoxazole, an antibiotic cladribine, used to treat hairy cell leukaemia
dożi għolja ta’ co-trimoxazole, antibijotiku cladribine, użata biex tikkura l-lewkimja taċ-ċelluli ċiljati

high doses of trimethoprim/sulfamethoxazole, an antibiotic cladribine, used to treat hairy cell leukaemia
dożi għolja ta’ trimethoprim/sulfamethoxazole, anti-bijotiku cladribine, użata biex tikkura l-lewkimja taċ-ċelluli ċiljati

high doses of co-trimoxazole, an antibiotic. cladribine (used to treat hairy cell leukaemia).
dożi għoljin ta’ co-trimoxazole, antibijotiku. cladribine (użat għall-kura ta’ lewkimja ta’ ċelloli sufin).

forty-three percent of patients with hairy cell leukaemia experienced infectious complications at standard dose regimen.
tlieta u erbgħin fil-mija tal-pazjenti b’lewkimja taċ-ċelluli ċiljati kellhom komplikazzjonijiet infettivi bir-reġimen ta’ doża stàndard.

cladribine, used to treat hairy cell leukaemia rifampicin, to treat tuberculosis (tb) and other bacterial infections
cladribine, użat għat-trattament ta’ lewkimja ta’ ċelloli ċiljati rifampicin, użat għat-trattament ta’ tuberkolożi (tb) u infezzjonijiet batterjali oħrajn

cladribine – used to treat hairy cell leukaemia. antacids containing aluminium and/or magnesium – used for heartburn.
cladribine – użat biex jikkura lewkimja tal-‘hairy cell’. antaċidi li fihom aluminju u/jew manjeżju - użati għal ħruq ta’ stonku.

for most patients with hairy cell leukaemia, normalisation of one or more haematological variables occurs within one to two months of introna treatment.
fil-biċċa l-kbira tal- pazjenti bil-lewkimja tal-hairy cell, in-normalizzazzjoni ta’ kwantità varjabbli ematoloġika waħda jew aktar isseħħ fi żmien xahar sa xahrejn ta’ kura b’introna.

 235 most patients with hairy cell leukaemia, normalisation of one or more haematological variables occurs within one to two months of introna treatment.
fil- biċċa l- kbira tal- pazjenti bil- lewkimja tal- hairy cell, in- normalizzazzjoni ta ’ kwantità varjabbli ematoloġika waħda jew aktar isseħħ fi żmien xahar sa xahrejn tat- trattament b’ introna.

fever of unknown origin frequently occurs in patients treated for hairy cell leukaemia and is manifested predominantly during the first 4 weeks of therapy.
deni li l-oriġini tiegħu mhix magħrufa jseħħ ta’ spiss f’pazjenti ttrattati għal-lewkimja taċ-ċelluli ċiljati u ġeneralment jidher matul l-ewwel 4 ġi mgħat tat-terapija.

the frequency of second malignancy following treatment with litak was 3.4% in all 232 hairy cell leukaemia patients treated, during a 10-year period.
il- frekwenza tat-tieni malinn wara t-trattament b’litak kienet ta’ 3.4% fil-232 pazjenti kollha li kellhom il-lewkimja taċ-ċelluli ċiljati matul kura f’perijodu ta’ 10 snin.

hairy cell leukaemia: 2 million iu/m2, 3 times a week (every other day) injected subcutaneously (under the skin).
lewkimja tal-hairy cell: 2 miljun iu/m², 3 darbiet fil-ġimgħa (darba kull jumejn) injettati taħt il- ġilda.

acute, irreversible neuro- and nephrotoxicity have been described in individual patients treated at a dose which was ≥ 4 times higher than the recommended regimen for hairy cell leukaemia.
newro- u nefro-tossiċità akuta irriversibbli, ġew deskritti f’pazjenti individwali ttrattati b’doża li kienet ≥ 4 aktar mir-reġimen rakkomandat għal- lewkimja taċ-ċelluli ċiljati.

uth in hairy cell leukaemia up to 100 miu/ m2/ week in melanoma), the most commonly reported undesirable effects were fever, fatigue, headache and myalgia.
ux mhux mixtieqa li kienu rrappurtati ta’ spiss kienu d- deni, għeja kbira, uġigħ ta ’ ras u uġigħ fil- muskoli.

in a compassionate use programme, mozobil and g-csf have been administered to patients with acute myelogenous leukaemia and plasma cell leukaemia.
fi programm ta’ użu kompassjonali, mozobil u g-csf ingħataw lil pazjenti b’lewkimja majeloġenika akuta u lewkimja taċ-ċelluli tal-plażma.

the cumulative frequencies of second malignancy are 5%, 10-12% and 13-14% following 5, 10 and 15 years respectively after diagnosis of hairy cell leukaemia.
il- frekwenzi kumulattivi ta’ malinni sekondarji huma ta’ 5%, 10-12% u 13-14% wara 5, 10 u 15-il sena rispettivament mid-dijanjożi tal-lewkimja taċ-ċelluli ċiljati.